InsidersTradesSigma
Total declarations
Companies
▲ Purchases (18 ops.)
▼ Sales (4 ops.)
Explore the detailed record of transactions filed by ARMISTICE CAPITAL, LLC. Director active across 7 companies, notably Aytu Biopharma, INC. Cumulatively, 30 disclosures have been logged. Total volume traded: €6.8m. The latest transaction was disclosed on 10 March 2022 — Acquisition. Regulator: SEC (Form 4). All data is openly available.
Declarations30 total
€16,45926,000 shares@ €0.6330.0049% mcap1.3% of flow
Common Stock
SEC:0000899243-22-010904:0·
Ideal exit: 5 Dec 2022 (T+270)
€32,12250,000 shares@ €0.64240.0096% mcap2.5% of flow
Common Stock
SEC:0000899243-22-009744:0·
Ideal exit: 28 Nov 2022 (T+270)
€70,840100,000 shares@ €0.70840.021% mcap5.6% of flow
Common Stock
SEC:0000899243-22-008145:0·
Ideal exit: 21 Nov 2022 (T+270)
€107,470150,000 shares@ €0.71650.032% mcap8.5% of flow
Common Stock
SEC:0000899243-22-007249:0·
Ideal exit: 14 Nov 2022 (T+270)
€159,698206,300 shares@ €0.774130.6% of flow
Common Stock
SEC:0000899243-22-002693·
Ideal exit: 15 Oct 2022 (T+270)
€159,698206,300 shares@ €0.77410.048% mcap12.6% of flow
Common Stock
SEC:0000899243-22-002693:0·
Ideal exit: 15 Oct 2022 (T+270)
€52,59457,300 shares@ €0.917910.1% of flow
Common Stock
SEC:0000899243-22-002025·
Ideal exit: 9 Oct 2022 (T+270)
€52,59457,300 shares@ €0.91790.016% mcap4.1% of flow
Common Stock
SEC:0000899243-22-002025:0·
Ideal exit: 9 Oct 2022 (T+270)
€126,561137,900 shares@ €0.91780.038% mcap10.0% of flow
Common Stock
SEC:0000899243-22-001618:0·
Ideal exit: 4 Oct 2022 (T+270)
€126,561137,900 shares@ €0.917824.3% of flow
Common Stock
SEC:0000899243-22-001618·
Ideal exit: 4 Oct 2022 (T+270)
€182,69795,455 shares@ €1.91435.0% of flow
Common Stock
SEC:0000899243-21-036402·
Ideal exit: 12 Jun 2022 (T+270)
€182,69795,455 shares@ €1.9140.054% mcap14.4% of flow
Common Stock
SEC:0000899243-21-036402:0·
Ideal exit: 12 Jun 2022 (T+270)
€70,15130,000 shares@ €2.338423.6% of flow
Common Stock
SEC:0000899243-21-033505·
Ideal exit: 13 May 2022 (T+270)
€70,15130,000 shares@ €2.33849.3% of flow
Common Stock
SEC:0000899243-21-033505:0·
Ideal exit: 13 May 2022 (T+270)
€226,899100,000 shares@ €2.26976.4% of flow
Common Stock
SEC:0001567619-21-014631·
Ideal exit: 1 May 2022 (T+270)
€226,899100,000 shares@ €2.26930.1% of flow
Common Stock
SEC:0001567619-21-014631:0·
Ideal exit: 1 May 2022 (T+270)
€154,34568,188 shares@ €2.26354.3% of flow
Common Stock
SEC:0001567619-21-014361·
€154,34568,188 shares@ €2.26352.1% of flow
Common Stock
SEC:0001567619-21-014361:0·
€3m852,500 shares@ €4.059895.7% of flow
Common Stock
SEC:0000899243-21-030722·
€3m852,500 shares@ €4.059847.9% of flow
Common Stock
SEC:0000899243-21-030722:0·
1,479,713 shares
Common Stock
SEC:0000919574-21-004321·
1,479,713 shares
Common Stock
SEC:0000919574-21-004321:0·
€2m388,045 shares@ €5.4353100.0% of flow
Common Stock
SEC:0000919574-21-004191·
5,330,277 shares
Common Stock
SEC:0000919574-21-004187·
€2m388,045 shares@ €5.435350.0% of flow
Common Stock
SEC:0000919574-21-004191:0·
25 of 30 declarations
About ARMISTICE CAPITAL, LLC
ARMISTICE CAPITAL, LLC is a significant shareholder of AYTU BIOPHARMA, INC.
